Today, Thursday, the European Medicines Agency approved the emergency use of Pfizer’s anti-coronavirus drug, PAXLOVID.
Today, Tuesday, Pfizer revealed that its drug showed very positive results.
And Pfizer said, in a statement on its website, that the final results of testing its oral anti-coronavirus drug, on 2,246 adults registered at this stage, showed that it significantly reduces the risk of death or hospitalization by 89%.
She added that she shared this data with the US Food and Drug Administration, as part of the ongoing application for an emergency use authorization for the drug.
And Pfizer explained that the results represent more confirmation that its anti-viral drug, if authorized or approved, can have a tangible impact on the lives of many, because the data further supports its effectiveness in reducing death and hospitalizations.
PAXLOVID is an antiviral treatment for the SARS-CoV-2 protease inhibitor. It has been developed to be given orally, so that it can be prescribed at the first sign of infection or upon first awareness of exposure, which may help patients avoid severe illness, which, if authorized or approved, could lead to hospitalization and death.